Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer

Shuji Arita, Tsuyoshi Shirakawa, Yuzo Matsushita, Hozumi Kumagai Shimokawa, Gen Hirano, Akitaka Makiyama, Yoshihiro Shibata, Shingo Tamura, Taito Esaki, Kenji Mitsugi, hiroshi ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.

Original languageEnglish
Pages (from-to)1959-1966
Number of pages8
JournalAnticancer Research
Volume36
Issue number4
Publication statusPublished - Apr 1 2016

Fingerprint

Colorectal Neoplasms
Safety
Drug Therapy
Febrile Neutropenia
Medical Oncology
Leukopenia
Neutropenia
Terminology
Disease-Free Survival
Comorbidity
Anemia
TAS 102
Survival
Population
regorafenib
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Arita, S., Shirakawa, T., Matsushita, Y., Shimokawa, H. K., Hirano, G., Makiyama, A., ... Baba, E. (2016). Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Research, 36(4), 1959-1966.

Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. / Arita, Shuji; Shirakawa, Tsuyoshi; Matsushita, Yuzo; Shimokawa, Hozumi Kumagai; Hirano, Gen; Makiyama, Akitaka; Shibata, Yoshihiro; Tamura, Shingo; Esaki, Taito; Mitsugi, Kenji; ariyama, hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.

In: Anticancer Research, Vol. 36, No. 4, 01.04.2016, p. 1959-1966.

Research output: Contribution to journalArticle

Arita, S, Shirakawa, T, Matsushita, Y, Shimokawa, HK, Hirano, G, Makiyama, A, Shibata, Y, Tamura, S, Esaki, T, Mitsugi, K, ariyama, H, Kusaba, H, Akashi, K & Baba, E 2016, 'Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer', Anticancer Research, vol. 36, no. 4, pp. 1959-1966.
Arita S, Shirakawa T, Matsushita Y, Shimokawa HK, Hirano G, Makiyama A et al. Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Research. 2016 Apr 1;36(4):1959-1966.
Arita, Shuji ; Shirakawa, Tsuyoshi ; Matsushita, Yuzo ; Shimokawa, Hozumi Kumagai ; Hirano, Gen ; Makiyama, Akitaka ; Shibata, Yoshihiro ; Tamura, Shingo ; Esaki, Taito ; Mitsugi, Kenji ; ariyama, hiroshi ; Kusaba, Hitoshi ; Akashi, Koichi ; Baba, Eishi. / Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. In: Anticancer Research. 2016 ; Vol. 36, No. 4. pp. 1959-1966.
@article{01e0399de24b4666b680f9e86a6d21af,
title = "Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer",
abstract = "Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37{\%}) were analyzed. Efficacy was reflected in an objective overall response of 3{\%}, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44{\%}), leukopenia (26{\%}) and anemia (23{\%}). Febrile neutropenia was found in 7{\%}. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.",
author = "Shuji Arita and Tsuyoshi Shirakawa and Yuzo Matsushita and Shimokawa, {Hozumi Kumagai} and Gen Hirano and Akitaka Makiyama and Yoshihiro Shibata and Shingo Tamura and Taito Esaki and Kenji Mitsugi and hiroshi ariyama and Hitoshi Kusaba and Koichi Akashi and Eishi Baba",
year = "2016",
month = "4",
day = "1",
language = "English",
volume = "36",
pages = "1959--1966",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer

AU - Arita, Shuji

AU - Shirakawa, Tsuyoshi

AU - Matsushita, Yuzo

AU - Shimokawa, Hozumi Kumagai

AU - Hirano, Gen

AU - Makiyama, Akitaka

AU - Shibata, Yoshihiro

AU - Tamura, Shingo

AU - Esaki, Taito

AU - Mitsugi, Kenji

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.

AB - Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.

UR - http://www.scopus.com/inward/record.url?scp=84984576826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984576826&partnerID=8YFLogxK

M3 - Article

C2 - 27069187

AN - SCOPUS:84984576826

VL - 36

SP - 1959

EP - 1966

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -